A new study published in The Lancet Psychiatry indicates that semaglutide, a GLP-1 weight-loss medication, is linked to lower risks of worsening mental disorders. Research involving over 95,000 participants showed a 42% reduced risk of worsening mental illness and a 44% lower risk for depression among users. The study highlights the complex relationship between weight loss, medication, and mental health, emphasizing the need for further clinical trials. Teljes cikk (Euronews.com)